CDK inhibitors in cancer therapy: what is next?
Trends Pharmacol Sci
; 29(1): 16-21, 2008 Jan.
Article
em En
| MEDLINE
| ID: mdl-18054800
ABSTRACT
The pursuit for drugs that inhibit cyclin-dependent kinases (CDKs) has been an intense area of research for more than 15 years. The first-generation inhibitors, Flavopiridol and CY-202, are in late-stage clinical trials, but so far have demonstrated only modest activity. Several second-generation inhibitors are now in clinical trials. Future approaches to determine clinical benefit need to incorporate both the lessons learned from these early compounds and information recently obtained from the genetic analysis of CDKs in preclinical models. Here we discuss key concepts that should be considered when validating the clinical utility of CDK inhibitors in cancer therapy.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Quinases Ciclina-Dependentes
/
Inibidores Enzimáticos
/
Neoplasias
/
Antineoplásicos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Trends Pharmacol Sci
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Espanha